Patient-derived  ||| S:0 E:16 ||| JJ
xenografts  ||| S:16 E:27 ||| NN
from  ||| S:27 E:32 ||| IN
non-small  ||| S:32 E:42 ||| JJ
cell  ||| S:42 E:47 ||| NN
lung  ||| S:47 E:52 ||| NN
cancer  ||| S:52 E:59 ||| NN
brain  ||| S:59 E:65 ||| NN
metastases  ||| S:65 E:76 ||| NNS
are  ||| S:76 E:80 ||| VBP
valuable  ||| S:80 E:89 ||| JJ
translational  ||| S:89 E:103 ||| JJ
platforms  ||| S:103 E:113 ||| NNS
for  ||| S:113 E:117 ||| IN
the  ||| S:117 E:121 ||| DT
development  ||| S:121 E:133 ||| NN
of  ||| S:133 E:136 ||| IN
personalized  ||| S:136 E:149 ||| JJ
targeted  ||| S:149 E:158 ||| JJ
therapy  ||| S:158 E:166 ||| NN
The  ||| S:166 E:170 ||| DT
increasing  ||| S:170 E:181 ||| JJ
prevalence  ||| S:181 E:192 ||| NN
of  ||| S:192 E:195 ||| IN
distant  ||| S:195 E:203 ||| JJ
metastases  ||| S:203 E:214 ||| NN
from  ||| S:214 E:219 ||| IN
non-small  ||| S:219 E:229 ||| JJ
cell  ||| S:229 E:234 ||| NN
lung  ||| S:234 E:239 ||| NN
cancer  ||| S:239 E:246 ||| NN
( ||| S:246 E:247 ||| -LRB-
NSCLC ||| S:247 E:252 ||| NNP
)  ||| S:252 E:254 ||| -RRB-
indicates  ||| S:254 E:264 ||| VBZ
an  ||| S:264 E:267 ||| DT
urgent  ||| S:267 E:274 ||| JJ
need  ||| S:274 E:279 ||| NN
for  ||| S:279 E:283 ||| IN
novel  ||| S:283 E:289 ||| JJ
therapeutic  ||| S:289 E:301 ||| JJ
modalities ||| S:301 E:311 ||| NN
.  ||| S:311 E:313 ||| .
Brain  ||| S:313 E:319 ||| NN
metastasis  ||| S:319 E:330 ||| NN
is  ||| S:330 E:333 ||| VBZ
particularly  ||| S:333 E:346 ||| RB
common  ||| S:346 E:353 ||| JJ
in  ||| S:353 E:356 ||| IN
NSCLC ||| S:356 E:361 ||| NNP
,  ||| S:361 E:363 ||| ,
with  ||| S:363 E:368 ||| IN
severe  ||| S:368 E:375 ||| JJ
adverse  ||| S:375 E:383 ||| JJ
effects  ||| S:383 E:391 ||| NNS
on  ||| S:391 E:394 ||| IN
clinical  ||| S:394 E:403 ||| JJ
prognosis ||| S:403 E:412 ||| NN
.  ||| S:412 E:414 ||| .
Although  ||| S:414 E:423 ||| IN
the  ||| S:423 E:427 ||| DT
molecular  ||| S:427 E:437 ||| JJ
heterogeneity  ||| S:437 E:451 ||| NN
of  ||| S:451 E:454 ||| IN
NSCLC  ||| S:454 E:460 ||| NNP
and  ||| S:460 E:464 ||| CC
availability  ||| S:464 E:477 ||| NN
of  ||| S:477 E:480 ||| IN
various  ||| S:480 E:488 ||| JJ
targeted  ||| S:488 E:497 ||| JJ
agents  ||| S:497 E:504 ||| NNS
suggest  ||| S:504 E:512 ||| VBP
personalized  ||| S:512 E:525 ||| VBN
therapeutic  ||| S:525 E:537 ||| JJ
approaches  ||| S:537 E:548 ||| NNS
for  ||| S:548 E:552 ||| IN
such  ||| S:552 E:557 ||| JJ
brain  ||| S:557 E:563 ||| NN
metastases ||| S:563 E:573 ||| NN
,  ||| S:573 E:575 ||| ,
further  ||| S:575 E:583 ||| JJ
development  ||| S:583 E:595 ||| NN
of  ||| S:595 E:598 ||| IN
appropriate  ||| S:598 E:610 ||| JJ
preclinical  ||| S:610 E:622 ||| JJ
models  ||| S:622 E:629 ||| NNS
is  ||| S:629 E:632 ||| VBZ
needed  ||| S:632 E:639 ||| VBN
to  ||| S:639 E:642 ||| TO
validate  ||| S:642 E:651 ||| VB
the  ||| S:651 E:655 ||| DT
strategies ||| S:655 E:665 ||| NNS
.  ||| S:665 E:667 ||| .
We  ||| S:667 E:670 ||| PRP
established  ||| S:670 E:682 ||| VBD
patient-derived  ||| S:682 E:698 ||| JJ
xenografts  ||| S:698 E:709 ||| NNS
( ||| S:709 E:710 ||| -LRB-
PDX ||| S:710 E:713 ||| NNP
)  ||| S:713 E:715 ||| -RRB-
using  ||| S:715 E:721 ||| VBG
NSCLC  ||| S:721 E:727 ||| NNP
brain  ||| S:727 E:733 ||| NN
metastasis  ||| S:733 E:744 ||| VBZ
surgical  ||| S:744 E:753 ||| JJ
samples  ||| S:753 E:761 ||| NNS
and  ||| S:761 E:765 ||| CC
elucidated  ||| S:765 E:776 ||| VB
their  ||| S:776 E:782 ||| PRP$
possible  ||| S:782 E:791 ||| JJ
preclinical  ||| S:791 E:803 ||| NN
and  ||| S:803 E:807 ||| CC
clinical  ||| S:807 E:816 ||| JJ
implications  ||| S:816 E:829 ||| NNS
for  ||| S:829 E:833 ||| IN
personalized  ||| S:833 E:846 ||| JJ
treatment ||| S:846 E:855 ||| NN
.  ||| S:855 E:857 ||| .
NSCLC  ||| S:857 E:863 ||| NNP
brain  ||| S:863 E:869 ||| NN
metastases  ||| S:869 E:880 ||| NNS
( ||| S:880 E:881 ||| -LRB-
n  ||| S:881 E:883 ||| CD
=  ||| S:883 E:885 ||| SYM
34 ||| S:885 E:887 ||| CD
)  ||| S:887 E:889 ||| -RRB-
showed  ||| S:889 E:896 ||| VBD
a  ||| S:896 E:898 ||| DT
significantly  ||| S:898 E:912 ||| RB
higher  ||| S:912 E:919 ||| RBR
successful  ||| S:919 E:930 ||| JJ
PDX  ||| S:930 E:934 ||| NNP
establishment  ||| S:934 E:948 ||| NN
rate  ||| S:948 E:953 ||| NN
than  ||| S:953 E:958 ||| IN
primary  ||| S:958 E:966 ||| JJ
specimens  ||| S:966 E:976 ||| NNS
( ||| S:976 E:977 ||| -LRB-
n  ||| S:977 E:979 ||| CD
=  ||| S:979 E:981 ||| SYM
64 ||| S:981 E:983 ||| CD
;  ||| S:983 E:985 ||| :
74 ||| S:985 E:987 ||| CD
%  ||| S:987 E:989 ||| NN
vs.  ||| S:989 E:993 ||| IN
23 ||| S:993 E:995 ||| CD
% ||| S:995 E:996 ||| NN
) ||| S:996 E:997 ||| -RRB-
.  ||| S:997 E:999 ||| .
PDXs  ||| S:999 E:1004 ||| JJ
derived  ||| S:1004 E:1012 ||| NN
from  ||| S:1012 E:1017 ||| IN
NSCLC  ||| S:1017 E:1023 ||| NNP
brain  ||| S:1023 E:1029 ||| NN
metastases  ||| S:1029 E:1040 ||| NNS
recapitulated  ||| S:1040 E:1054 ||| VBP
the  ||| S:1054 E:1058 ||| DT
pathologic ||| S:1058 E:1068 ||| NN
,  ||| S:1068 E:1070 ||| ,
genetic ||| S:1070 E:1077 ||| JJ
,  ||| S:1077 E:1079 ||| ,
and  ||| S:1079 E:1083 ||| CC
functional  ||| S:1083 E:1094 ||| JJ
properties  ||| S:1094 E:1105 ||| NNS
of  ||| S:1105 E:1108 ||| IN
corresponding  ||| S:1108 E:1122 ||| JJ
parental  ||| S:1122 E:1131 ||| JJ
tumors ||| S:1131 E:1137 ||| NNS
.  ||| S:1137 E:1139 ||| .
Furthermore ||| S:1139 E:1150 ||| RB
,  ||| S:1150 E:1152 ||| ,
tumor  ||| S:1152 E:1158 ||| NN
spheres  ||| S:1158 E:1166 ||| VBZ
established  ||| S:1166 E:1178 ||| VBN
in  ||| S:1178 E:1181 ||| IN
vitro  ||| S:1181 E:1187 ||| NN
from  ||| S:1187 E:1192 ||| IN
the  ||| S:1192 E:1196 ||| DT
xenografts  ||| S:1196 E:1207 ||| NN
under  ||| S:1207 E:1213 ||| IN
serum-free  ||| S:1213 E:1224 ||| JJ
conditions  ||| S:1224 E:1235 ||| NNS
maintained  ||| S:1235 E:1246 ||| VBD
their  ||| S:1246 E:1252 ||| PRP$
in  ||| S:1252 E:1255 ||| FW
vivo  ||| S:1255 E:1260 ||| FW
brain  ||| S:1260 E:1266 ||| FW
metastatic  ||| S:1266 E:1277 ||| FW
potential ||| S:1277 E:1286 ||| NN
.  ||| S:1286 E:1288 ||| .
Differential  ||| S:1288 E:1301 ||| JJ
phenotypic  ||| S:1301 E:1312 ||| NN
and  ||| S:1312 E:1316 ||| CC
molecular  ||| S:1316 E:1326 ||| JJ
responses  ||| S:1326 E:1336 ||| NNS
to  ||| S:1336 E:1339 ||| TO
20  ||| S:1339 E:1342 ||| CD
targeted  ||| S:1342 E:1351 ||| JJ
agents  ||| S:1351 E:1358 ||| NNS
could  ||| S:1358 E:1364 ||| MD
subsequently  ||| S:1364 E:1377 ||| RB
be  ||| S:1377 E:1380 ||| VB
screened  ||| S:1380 E:1389 ||| VBN
in  ||| S:1389 E:1392 ||| IN
vitro  ||| S:1392 E:1398 ||| NNS
using  ||| S:1398 E:1404 ||| VBG
these  ||| S:1404 E:1410 ||| DT
NSCLC  ||| S:1410 E:1416 ||| NNP
PDXs  ||| S:1416 E:1421 ||| NNP
derived  ||| S:1421 E:1429 ||| VBD
from  ||| S:1429 E:1434 ||| IN
brain  ||| S:1434 E:1440 ||| NN
metastases ||| S:1440 E:1450 ||| NN
.  ||| S:1450 E:1452 ||| .
Although  ||| S:1452 E:1461 ||| IN
PDX  ||| S:1461 E:1465 ||| NNP
establishment  ||| S:1465 E:1479 ||| NN
from  ||| S:1479 E:1484 ||| IN
primary  ||| S:1484 E:1492 ||| JJ
NSCLCs  ||| S:1492 E:1499 ||| NN
was  ||| S:1499 E:1503 ||| VBD
significantly  ||| S:1503 E:1517 ||| RB
influenced  ||| S:1517 E:1528 ||| VBN
by  ||| S:1528 E:1531 ||| IN
histologic  ||| S:1531 E:1542 ||| JJ
subtype ||| S:1542 E:1549 ||| NN
,  ||| S:1549 E:1551 ||| ,
clinical  ||| S:1551 E:1560 ||| JJ
aggressiveness ||| S:1560 E:1574 ||| NN
,  ||| S:1574 E:1576 ||| ,
and  ||| S:1576 E:1580 ||| CC
genetic  ||| S:1580 E:1588 ||| JJ
alteration  ||| S:1588 E:1599 ||| JJ
status ||| S:1599 E:1605 ||| NN
,  ||| S:1605 E:1607 ||| ,
the  ||| S:1607 E:1611 ||| DT
brain  ||| S:1611 E:1617 ||| NN
metastases  ||| S:1617 E:1628 ||| VBZ
exhibited  ||| S:1628 E:1638 ||| VBN
consistently  ||| S:1638 E:1651 ||| RB
adequate  ||| S:1651 E:1660 ||| JJ
in  ||| S:1660 E:1663 ||| IN
vivo  ||| S:1663 E:1668 ||| JJ
tumor  ||| S:1668 E:1674 ||| NN
take  ||| S:1674 E:1679 ||| VB
rate  ||| S:1679 E:1684 ||| NN
and  ||| S:1684 E:1688 ||| CC
in  ||| S:1688 E:1691 ||| IN
vitro  ||| S:1691 E:1697 ||| JJ
tumor  ||| S:1697 E:1703 ||| NN
sphere  ||| S:1703 E:1710 ||| NN
formation  ||| S:1710 E:1720 ||| NN
capacity ||| S:1720 E:1728 ||| NN
,  ||| S:1728 E:1730 ||| ,
regardless  ||| S:1730 E:1741 ||| RB
of  ||| S:1741 E:1744 ||| IN
clinical  ||| S:1744 E:1753 ||| JJ
and  ||| S:1753 E:1757 ||| CC
molecular  ||| S:1757 E:1767 ||| JJ
conditions ||| S:1767 E:1777 ||| NNS
.  ||| S:1777 E:1779 ||| .
Therefore ||| S:1779 E:1788 ||| RB
,  ||| S:1788 E:1790 ||| ,
PDXs  ||| S:1790 E:1795 ||| JJ
from  ||| S:1795 E:1800 ||| IN
NSCLC  ||| S:1800 E:1806 ||| NNP
brain  ||| S:1806 E:1812 ||| NN
metastases  ||| S:1812 E:1823 ||| NNS
may  ||| S:1823 E:1827 ||| MD
better  ||| S:1827 E:1834 ||| RB
represent  ||| S:1834 E:1844 ||| VB
the  ||| S:1844 E:1848 ||| DT
heterogeneous  ||| S:1848 E:1862 ||| NN
advanced  ||| S:1862 E:1871 ||| VBD
NSCLC  ||| S:1871 E:1877 ||| NNP
population  ||| S:1877 E:1888 ||| NN
and  ||| S:1888 E:1892 ||| CC
could  ||| S:1892 E:1898 ||| MD
be  ||| S:1898 E:1901 ||| VB
utilized  ||| S:1901 E:1910 ||| VBN
as  ||| S:1910 E:1913 ||| IN
preclinical  ||| S:1913 E:1925 ||| JJ
models  ||| S:1925 E:1932 ||| NNS
to  ||| S:1932 E:1935 ||| TO
meet  ||| S:1935 E:1940 ||| VB
unmet  ||| S:1940 E:1946 ||| JJ
clinical  ||| S:1946 E:1955 ||| NN
needs  ||| S:1955 E:1961 ||| VBZ
such  ||| S:1961 E:1966 ||| JJ
as  ||| S:1966 E:1969 ||| IN
drug  ||| S:1969 E:1974 ||| NN
screening  ||| S:1974 E:1984 ||| NN
for  ||| S:1984 E:1988 ||| IN
personalized  ||| S:1988 E:2001 ||| JJ
treatments ||| S:2001 E:2011 ||| NNS
.  ||| S:2011 E:2013 ||| .
